Stockscreener 앱 받기
52.87
0.51%
0.27
시간 외 거래:
52.29
-0.58
-1.10%
전일 마감가:
$52.60
열려 있는:
$52.43
하루 거래량:
3.13M
Relative Volume:
1.53
시가총액:
$5.55B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.87%
1개월 성능:
+44.85%
6개월 성능:
+304.20%
1년 성능:
+0.00%
1일 변동 폭
$52.09
$52.93
1주일 범위
$52.09
$53.20
52주 변동 폭
$12.30
$54.47
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
52.87 | 5.54B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | Wells Fargo | Overweight |
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
모두보기
Metsera Inc 주식(MTSR)의 최신 뉴스
Metsera (NASDAQ:MTSR) Receives Sell (D) Rating from Weiss Ratings - MarketBeat
Metsera Inc. stock trend forecastJuly 2025 Action & Smart Allocation Stock Tips - newser.com
How to integrate Metsera Inc. into portfolio analysis toolsQuarterly Profit Summary & AI Enhanced Trading Signals - newser.com
Pfizer Aims To Close Gap On Obesity Drugs With Metsera 09/23/2025 - MediaPost
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates UNP, MTSR, SCS on Behalf of Shareholders - The Malaysian Reserve
What data driven models say about Metsera Inc.’s futureJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Does Metsera Inc. show high probability of reboundSwing Trade & Accurate Intraday Trading Signals - newser.com
Is Metsera Inc. stock near bottom after declineJuly 2025 Market Mood & Weekly Breakout Stock Alerts - newser.com
Will Metsera Inc. rebound enough to break even2025 Market Sentiment & Consistent Income Trade Ideas - newser.com
Applying Elliott Wave Theory to Metsera Inc.Weekly Stock Analysis & Technical Pattern Based Signals - newser.com
Pfizer: Mastering The Art Of The Deal With MetseraUpgraded To Buy (NYSE:PFE) - Seeking Alpha
Pfizer to Buy Metsera for $4.9 Billion in Obesity Drug Bet - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Down 50%, Should You Buy the Dip on Pfizer? - The Motley Fool
Is this a good reentry point in Metsera Inc.Exit Point & Consistent Return Investment Signals - newser.com
Is Metsera Inc. stock poised for growthWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Will earnings trigger a reversal in Metsera Inc.July 2025 PostEarnings & Verified Trade Idea Suggestions - newser.com
Is Metsera Inc. stock resilient to inflationJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Market Movers: Metsera and Apple surge, Kenvue falters on Tylenol troubles - MSN
Where Metsera’s data fit in the obesity landscape - BioCentury
Will Metsera Inc. stock split again soonWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
Metsera (NASDAQ:MTSR) Raised to "Hold" at Wall Street Zen - MarketBeat
Metsera’s Phase IIb GLP-1 Data Show Competitive Efficacy, Tolerability - insights.citeline.com
Metsera strengthens case for Pfizer buyout with latest study data - BioPharma Dive
Metsera Reports Up To 14% Weight Loss In Phase 2b Obesity Trial - inkl
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 b - The Economic Times
PFE stock rises 5.3% today: Pfizer seals Trump drug price deal with $70 billion U.S. investment and $7.3 billion Metsera weight-loss acquisition - MSN
Metsera Posts Promising Weight-Loss Drug Results. It Could Be a Win for Pfizer. - Barron's
Pfizer M&A prospect Metsera heads to phase III with lead GLP-1 - BioWorld MedTech
Trump’s MFN deadline came and went - statnews.com
Metsera’s Obesity Drug Shows 'Very Encouraging' Mid-Stage Efficacy, Supporting Pfizer’s $4.9B Bet - BioSpace
Metsera (NASDAQ:MTSR) Cut to Equal Weight at Wells Fargo & Company - MarketBeat
Pfizer licking its lips as Metsera presents positive weight loss data - The Pharma Letter
Wells Fargo Downgrades Metsera to Equal Weight From Overweight, Cuts Price Target to $54 From $65 - MarketScreener
Metsera’s new obesity data mean Pfizer has side effect and efficacy questions to answer - Endpoints News
Pfizer's new prize Metsera touts 14% weight loss, 'class-leading tolerability' for lead GLP-1 drug - Fierce Biotech
Pfizer Acquires Metsera to Re-Enter Obesity Drug Arena - PharmiWeb.com
Pfizer-bound Metsera touts Phase II double-header for GLP-1 hopeful - FirstWord Pharma
Metsera’s weight loss drug shows 14.1% reduction in phase 2b trials - Investing.com Nigeria
Metsera started at buy at Guggenheim on obesity treatment potential - MSN
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Metsera Inc 주식 (MTSR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Burow Kristina | Director |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
5.74%
자본화:
|
볼륨(24시간):